Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 6/2009

01.12.2009 | Case Report

Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine

verfasst von: Dominique Levêque, Raoul Santucci, Julien Pavillet, Raoul Herbrecht, Jean Pierre Bergerat

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Case description A French Caucasian man aged 39 with HIV infection was treated with abacavir/lamivudine and ritonavir/lopinavir. The patient (normal renal and liver functions) was diagnosed with a Burkitt lymphoma for which he was treated with cyclophosphamide day 1 to 5; doxorubicin day 1; methotrexate day 10; and vincristine day 1 and 8. At day 12, he suffered from abdominal pain associated with constipation. Paralytic ileus was diagnosed by study imaging. Ileus lasted 10 days necessitating parenteral feeding. Later on, a further cycle of chemotherapy with etoposide replacing vincristine was given and was well tolerated. Conclusion We speculate that an interaction between ritonavir/lopinavir and vincristine was responsible for this severe toxicity. Vincristine is transported by P-gp and is metabolized via CYP3A5. Ritonavir is a potent CYP3A5 isoenzyme and P-gp inhibitor. Lopinavir is also a P-gp inhibitor. Ritonavir and lopinavir might have delayed vincristine elimination. Clinicians should be aware of this possible interaction.
Literatur
1.
Zurück zum Zitat Levêque D, Jehl F. Molecular pharmacokinetics of catharanthus (vinca) alkaloids. J Clin Pharmacol. 2007;47:579–88.CrossRefPubMed Levêque D, Jehl F. Molecular pharmacokinetics of catharanthus (vinca) alkaloids. J Clin Pharmacol. 2007;47:579–88.CrossRefPubMed
2.
Zurück zum Zitat Toghill PJ, Burke JD. Death from paralytic ileus following vincristine therapy. Postgrad Med J. 1970;46:330–1.CrossRefPubMed Toghill PJ, Burke JD. Death from paralytic ileus following vincristine therapy. Postgrad Med J. 1970;46:330–1.CrossRefPubMed
3.
Zurück zum Zitat Bermudez M, Fuster JL, Llinares E, Galera A, Gonzales C. Itraconazole-related increased vincristine neurotoxicity. J Pediatr Hematol Oncol. 2005;27:389–92.CrossRefPubMed Bermudez M, Fuster JL, Llinares E, Galera A, Gonzales C. Itraconazole-related increased vincristine neurotoxicity. J Pediatr Hematol Oncol. 2005;27:389–92.CrossRefPubMed
4.
Zurück zum Zitat Harnicar S, Adel N, Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract. 2009;15:175–82.CrossRef Harnicar S, Adel N, Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract. 2009;15:175–82.CrossRef
5.
Zurück zum Zitat Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006;34:1317–27.CrossRefPubMed Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006;34:1317–27.CrossRefPubMed
6.
Zurück zum Zitat Dennison JB, Mohutsky MA, Barbuch RJ, Wrighton SA, Hall SD. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J Pharmacol Exp Ther. 2008;327:248–57.CrossRefPubMed Dennison JB, Mohutsky MA, Barbuch RJ, Wrighton SA, Hall SD. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J Pharmacol Exp Ther. 2008;327:248–57.CrossRefPubMed
7.
Zurück zum Zitat Quaranta S, Chevalier D, Allorge D, Lo-Guidice JM, Migot-Nabias F, Kenani A, et al. Ethnic differences in the distribution of CYP3A5 gene polymorphisms. Xenobiotica. 2006;36:1191–200.CrossRefPubMed Quaranta S, Chevalier D, Allorge D, Lo-Guidice JM, Migot-Nabias F, Kenani A, et al. Ethnic differences in the distribution of CYP3A5 gene polymorphisms. Xenobiotica. 2006;36:1191–200.CrossRefPubMed
8.
Zurück zum Zitat Ernest CS, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005;312:83–91. Ernest CS, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005;312:83–91.
9.
Zurück zum Zitat Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol. 2007;73:1573–81.CrossRefPubMed Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol. 2007;73:1573–81.CrossRefPubMed
10.
Zurück zum Zitat Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non Hodgkin lymphoma. Cancer. 2001;91:155–63.CrossRefPubMed Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non Hodgkin lymphoma. Cancer. 2001;91:155–63.CrossRefPubMed
Metadaten
Titel
Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine
verfasst von
Dominique Levêque
Raoul Santucci
Julien Pavillet
Raoul Herbrecht
Jean Pierre Bergerat
Publikationsdatum
01.12.2009
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 6/2009
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-009-9323-y

Weitere Artikel der Ausgabe 6/2009

International Journal of Clinical Pharmacy 6/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.